ABOUT US

In 1898, eminent surgeon Dr. Roswell Park established the world’s first institution dedicated to cancer research and created a powerful force by bringing together the knowledge and skills of pathologists, chemists, biologists, surgeons and other experts – all in one center.

His vision built a dynamic research engine that became a model for other cancer centers around the world.

World’s first clinical trial using two-gene combination for T-cell engineering

OUR HISTORY OF SUCCESS

Our focus on cancer has unleashed more than a century of discovery and innovation that led to many game-changers in the fight against cancer, including:

- PSA screening test for prostate cancer
- RPMI 1640 culture medium used worldwide
- Photodynamic therapy
- Photoclor, a next-generation photosensitizing drug
- 5-FU + leucovorin therapy, now the standard of care for colorectal cancer
- RoSS simulator to train robotic surgeons
- OmniSeq®, a suite of diagnostics to match patients with treatment options based on comprehensive genomic sequencing and immune profiling
- Prolivy™, a targeted immunotherapy for lymphoma
We understand the challenges of moving novel technologies from the bench to the bedside and we are eager to work with industry partners and entrepreneurs to advance cancer treatment.

Our industry partnering activities and translational research model speed the progress of promising ideas from one phase of research to the next, through clinical trials that accelerate new treatments from the lab to the patients who need them.

_TOMORROW’S NEW CELLULAR THERAPY, CANCER DRUG, DIAGNOSTIC, OR SURGICAL DEVICE MAY ALREADY BE HERE._

**OUR TECHNOLOGIES**

We have more than 170 innovations ready for advancement, development, licensing, and transfer to the marketplace, such as these novel approaches for:

- **OVARIAN CANCER**: Novel armed CAR-T therapy
- **ESOPHAGEAL CANCER**: Targeting glucose-stimulated phosphohistidine signaling
- **HER2 POSITIVE CANCERS**: Treating with prolidase

**CONTACT US**

Patrick Emmerling, PhD, MBA, CLP
Director of Technology Transfer & Commercial Development
Patrick.Emmerling@RoswellPark.org
716-845-1300 x6955

---

**AVAILABLE TECHNOLOGIES BY TYPE**

- 45 Therapeutics/Vaccines
- 24 Diagnostics
- 22 Medical Devices
- 17 Cellular Therapies
- 6 Imaging Reagents
- 15 Research Reagents
- 21 Methods of Treatment
- 24 Other (biomarkers, software, lab processes, etc.)
- 17 Diagnostics

---